Repros Therapeutics

Repros Therapeutics — Investor Presentation (April 2015)

21 slides from Repros Therapeutics's investor presentation, Apr 8, 2015

  1. Slide 1: Enclomiphene (fka Androxal): A Mechanistically Consistent Approach to Secondary Hypogonadism

    Enclomiphene ( fka Androxal®) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai

  3. Slide 3: Greater Effects of BMI on Reproductive Hormone Levels in EMAS

    he last course Primary Greater Effects of BMI (cf to Age) on Reproductive Hormone Levels in EMAS - Indicating Secondary Hypogonadism in Obesity (n= 3210) Tesorone molt Ste Tesonterone pelt) mt crane i rere Ss ieee co aes ef ____ Pea Pe eg oe Aor "Wu et ak JCEM 2008

  4. Slide 4: Androxal Trans Isomer of Clomiphene, Pure Estrogen Antagonist

    Androxal (Patented) Trans Isomer (Pure Estrogen Antagonist) of Clomiphene Commercial Clomid (60% Trans, 40% Cis) 0 20 40 60 80 100 0.01 1 100 10000 % Concentration ( nM ) Estrogen Receptor Binding Affinity zu cis Trough Concentration. of Androxal In Serum at Steady State Achieved within 10 Days Of A

  5. Slide 5: Clomiphene Isomers Exhibit Different Impact on Animal Urogenital Tract Tissues

    Clomiphene Isomers Exhibit Different Impact on Animal Urogenital Tract Tissues 0 5 10 15 20 25 Blood Testis Epididymis Seminal vesicles Kidneys ng Equivalent [ 14 C] clomiphene isomers /Kg Zuc 4 Hr Zuc 24 Hr Enc 4 Hr Enc 24 Hr

  6. Slide 6: Enclomiphene Regulatory Status

    Enclomiphene Regulatory Status • NDA accepted by FDA – Treatment of secondary hypogonadism in overweight men – NDA filing requests NCE (New Chemical Entity) status • EMA (European Medicines Agency) notes enclomiphene is eligible for submission for a centralized marketing authorisation application (M

  7. Slide 7: How Androxal Works

    How Androxal Works A ndroxal blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Endroxal LH Androgel LH LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250 300 350 400 450 50

  8. Slide 8: ZA-304 & ZA-305 Results: Androxal Yields Meaningful Reproducible Outcomes

    ZA - 304 & ZA - 305 Results Androxal Yields Meaningful Reproducible Outcomes Study ZA - 304 (p - values Treatment vs A ndroxal ) ZA - 305 (p - values Treatment vs A ndroxal ) Treatment Androxal Androgel Placebo Androxal Androgel Placebo N 41 43 45 44 42 41 Age (SD) 49.1 (7.4) 47.4 (7.2) 47.2 (9.0) 4

  9. Slide 9: Androxal Exhibits No Negative Effects on Spermatogenesis Unlike Exogenous T

    Androxal Exhibits No Negative Effects on Spermatogenesis Unlike Exogenous T -70 -60 -50 -40 -30 -20 -10 0 10 20 % Change from Baseline Impact on Sperm Concentration After 16 Wks Treatment ZA - 304 Endroxal Androgel Placebo 0 10 20 30 40 50 60 % of Oligospermic Subjects % of Subjects Becoming Oligosp

  10. Slide 10: Androxal Averages Majority of Men Studied in Normal Range

    Androxal Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Androxal Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3 Mo. 68.

  11. Slide 11: What Predicts Response?

    What Predicts Response? • How long has subject been diagnosed as secondary hypogonadal? – Obesity suppresses responsiveness of the HPT axis • Previous TRT lessens response to Androxal – Drastically suppresses HPT axis • Should intervention in the obese male start sooner – Age related morning T – T <

  12. Slide 12: Initial Screening Findings for ZA-304 & ZA-305

    Initial Screening Findings for ZA - 304 & 305 Age ≤ 60, BMI > 25 Category Number of Men Age Mean ( StDev ) T ng/ dL ** Mean ( StDev ) BMI Mean ( StDev ) Total Screened 642 47.5 (8.6) 267 (83.6) 33.3 (4.6) Randomized 256 47.3 (8.3) 237 (43.8) 33.4 (4.4) Screen Failed 386 BMI>42 2 48 (5.7) - - Eye Exa

  13. Slide 13: Overweight Men Exhibit Lower Than Normal T Compared to Aged Matched Controls

    Overweight Men Exhibit Lower Than Normal T Compared to Aged Matched Controls 0 20 40 60 80 100 N= Distribution of Morning T for Men Screen Failing Due to High T Mean Age: 46.3 100 300 500 700 900 Framingham Heart Study 40- 49 Framingham Heart Study 50- 59 European Male Aging Study 40-49 European Mal

  14. Slide 14: Influence of Prior Testosterone on Response

    Influence of Prior Testosterone on Response ZA - 300, 6 month study

  15. Slide 15: Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement

    Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Androxal Advantages – Oral – Not controlled substance, cannot be abused – No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testicular function) – Does not

  16. Slide 16: Sales of Testosterone and Clomiphene

    $ Sales of Testosterone and Clomiphene 0 100 200 300 400 500 600 700 0 50000 100000 150000 200000 250000 Clomiphene Retail Sales $(000) Testosterone Retail Sales $(000) Monthly Sales (January 2013 – November 2014) Testosterone clomiphene

  17. Slide 17: Androxal US Commercial Plan/Schedule

    Androxal US Commercial Plan/Schedule • Q2 - 15 – Orders placed for API and Drug Product – KOL Board in place and active – Publications and Scientific Mtgs – Hire Chief Commercial Officer • Q3 - 15 – Finish preparation for Adcom – Adcom ? – Continue Education – Commence pre - launch activities • Q4 -

  18. Slide 18: Preliminary Sales Footprint and Business Rules

    18 Preliminary footprint : 41 FT and 3 PT Business Rules Workload Assumptions : ▪ 6 calls per day ▪ FT: 210 working days ▪ PT: 137 working days ▪ Territory Workload: 1,260 calls for FT ▪ Territory Workload: 822 calls for PT Design Assumptions : ▪ Territory Radius: ~150 miles Frequency Assumptions: ▪

  19. Slide 19: New Endo & Uro Scenario Expense Budget

    NOTES : 1. The prior assumptions and caveats under the original scenario remain. 2. We believe that the only material change to these expenses are related to the size of the Sales Team. We have kept other expenses the same. Commercial Function Pre - Launch (Launch Minus 18 Months) Launch Year Launch

  20. Slide 20: Proellex Status and Plans Going Forward

    Proellex Status and Plans Going Forward • Ongoing Phase 2b Proellex studies – Uterine fibroids (vaginal and oral administration studies) • Rapid and maintained reduction in bleeding • Reduction of fibroid bulk • Reduction of bulk associated symptoms – Endometriosis • Rapid reduction in menstrual and

  21. Slide 21: Financial Summary

    Financial Summary • Cash and equivalents: (audited year - end 2014) $46.6 M • Estimated Burn in 2015 : $22.0 M • Cash runway: Through 2016 – Anticipate Androxal approved • Current shares outstanding: 24.3 M shares – Warrants Outstanding – Series A – 39,595 (purchased in unit deal @ $2.45); Series B

Repros Therapeutics — Investor Presentation (April 2015) on 6ix